Allo CAR-T & Aprepitant For EGFR TKI Pruritis
Oct 13, 2022•20 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
We discuss a phase I study (CALM) of an allogeneic anti-CD19 CART-T product, using aprepitant (?) for pruritis from EGFR TKIs, and the widely discussed NordICC study on colonoscopy screening.
CALM: https://doi.org/10.1016/S2352-3026(22)00245-9
Aprepitant vs. desloratidine: https://doi.org/10.1002/cncr.34474
NordICC: https://www.nejm.org/doi/full/10.1056/NEJMoa2208375
NordICC editorial: https://www.nejm.org/doi/full/10.1056/NEJMe2211595
For the best experience, listen in Metacast app for iOS or Android